Skip to main content

Oxandrolone Pregnancy and Breastfeeding Warnings

Brand names: Oxandrin

Medically reviewed by Last updated on Jun 10, 2024.

Oxandrolone Pregnancy Warnings

Use is contraindicated.

US FDA pregnancy category: X

-This drug has been shown to cause embryotoxicity, fetotoxicity, infertility, and masculinization of female animal offspring when given in doses 9 times the human dose.

This drug has not been tested in laboratory animals for carcinogenic or mutagenic effects. In 2-year chronic oral rat studies, a dose-related reduction of spermatogenesis and decreased organ weights (testes, prostate, seminal vesicles, ovaries, uterus, adrenals, and pituitary) were shown.

US FDA pregnancy category X: Studies in animals or humans have demonstrated fetal abnormalities and/or there is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience, and the risks involved in use of the drug in pregnant women clearly outweigh potential benefits.

See references

Oxandrolone Breastfeeding Warnings

A decision should be made to discontinue breastfeeding or discontinue the drug, taking into account the importance of the drug to the mother.

Excreted into human milk: Unknown
Excreted into animal milk: Data not available

-The effects in the nursing infant are unknown.

See references

References for pregnancy information

  1. (2001) "Product Information. Oxandrin (oxandrolone)." Bio-Tech

References for breastfeeding information

  1. (2001) "Product Information. Oxandrin (oxandrolone)." Bio-Tech

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.